Effect of withdrawal of somatostatin plus GH‐releasing hormone as a stimulus of GH secretion in obesity

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Endocrinology

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2265.2002.01487.xPMID 11966741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [The regulation of growth hormone secretion].

  2018influential reference
• Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.

  2001cited by this paper
• Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation.

  2000cited by this paper
• Development of obesity in transgenic rats with low circulating growth hormone levels: involvement of leptin resistance.

  2000cited by this paper
• GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.

  2000cited by this paper
• Obesity attenuates the growth hormone response to exercise.

  1999cited by this paper
• Somatostatin infusion withdrawal: studies in normal children and in children with growth hormone deficiency.

  1999cited by this paper
• Ghrelin is a growth-hormone-releasing acylated peptide from stomach

  1999cited by this paper
• Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

  1998cited by this paper
• Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.

  1998cited by this paper
• Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency.

  1998cited by this paper
• Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man.

  1997cited by this paper
• A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release

  1996cited by this paper
• The regulation of growth hormone secretion.

  1996cited by this paper
• Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.

  1996cited by this paper
• Sex-related alterations in hypothalamic growth hormone-releasing hormone mRNA-but not somatostatin mRNA-expressing cells in genetically obese Zucker rats.

  1996cited by this paper
• Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.

  1996cited by this paper
• Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.

  1996cited by this paper
• Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency.

  1996cited by this paper
• Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects.

  1995cited by this paper
• Influence of metabolic substrates and obesity on growth hormone secretion.

  1995cited by this paper
• Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects

  1995cited by this paper
• Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.

  1994cited by this paper
• A new dimension on the induced release of growth hormone in obese subjects.

  1993cited by this paper
• Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.

  1993cited by this paper
• Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.

  1991cited by this paper
• Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man.

  1991cited by this paper
• The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man

  1991cited by this paper
• Corticosteroid‐induced growth hormone secretion in normal and obese subjects

  1991cited by this paper
• Alteration of somatostatin but not growth hormone-releasing factor pituitary binding sites in obese Zucker rats.

  1991cited by this paper
• Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.

  1990cited by this paper
• Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.

  1990cited by this paper
• Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.

  1990cited by this paper
• Mechanisms of impaired growth hormone secretion in genetically obese Zucker rats: roles of growth hormone-releasing factor and somatostatin.

  1990cited by this paper
• Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.

  1989cited by this paper
• Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.

  1989cited by this paper
• The rebound release of growth hormone (GH) following somatostatin infusion in rats involves hypothalamic GH-releasing factor release.

  1988cited by this paper
• Combined effects of human growth hormone (GH)-releasing factor-44 (GRF) and somatostatin (SRIF) on post-SRIF rebound release of GH and prolactin: a model for GRF-SRIF modulation of secretion.

  1988cited by this paper
• Effect of withdrawal of somatostatin and growth hormone (GH)-releasing factor on GH release in vitro.

  1988cited by this paper
• Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.

  1988cited by this paper
• GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRH

  1987cited by this paper
• Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man.

  1986cited by this paper
• GROWTH HORMONE RESPONSE TO LOW DOSE INTRAVENOUS INJECTIONS OF GROWTH HORMONE RELEASING FACTOR IN OBESE AND NORMAL WEIGHT WOMEN

  1986cited by this paper
• Impaired growth hormone responses to growth hormone-releasing factor in obesity.

  1985cited by this paper
• Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction.

  1984cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Effects of Growth Hormone Treatment in Obese

  year unknowncited by this paper

• Endocrine Dysfunction Following Bariatric Surgery: A Systematic Review of Postoperative Changes in Major Endocrine Hormones

  2025cites this paper
• Sex-differential testosterone response to long-term weight loss

  2024cites this paper
• Circadian Changes in Gut Peptide Levels and Obesity

  2020cites this paper
• Early overnutrition sensitizes the growth hormone axis to the impact of diet-induced obesity via sex-divergent mechanisms

  2020cites this paper
• A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic

  2020cites this paper
• Metabolic and Endocrine Consequences of Bariatric Surgery

  2019cites this paper
• Alteraciones neuroendocrinas en la obesidad

  2017cites this paper
• Maternal obesity programs reduced leptin signaling in the pituitary and altered GH/IGF1 axis function leading to increased adiposity in adult sheep offspring

  2017cites this paper
• The Sleep/Wake Cycle is Directly Modulated by Changes in Energy Balance.

  2016cites this paper
• Ghrelin in obesity, physiological and pharmacological considerations.

  2013cites this paper
• Metabolic and Endocrine Physiology in Obesity

  2012cites this paper
• Alteraciones del anillo de Waldeyer y su relación con el retraso de crecimiento

  2012cites this paper
• [Endocrine function in obesity].

  2011influential citation
• Función endocrina en la obesidad

  2011cites this paper
• Recruiting of somatotroph cells after combined somatostatin, GHRH and growth hormone (GH) secretagogue stimulation in a study of pituitary GH reserve in prepuberal female rats.

  2006cites this paper
• Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function.

  2006cites this paper
• Effects of gastric bypass on the GH/IGF-I axis in severe obesity--and a comparison with GH deficiency.

  2006cites this paper
• Pubertal alterations in growth and body composition: IX. Altered spontaneous secretion and metabolic clearance of growth hormone in overweight youth.

  2005cites this paper
• Acipimox enhances spontaneous growth hormone secretion in obese women.

  2004cites this paper
• Marked GH secretion after ghrelin alone or combined with GH‐releasing hormone (GHRH) in obese patients

  2004cites this paper
• Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa.

  2003cites this paper
• Somatostatin and somatostatin receptor physiology

  2003cites this paper
• Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.

  2003cites this paper
• ENDOCRINOLOGÍA Y NUTRICIÓN

  year unknowncites this paper